Russia authorizes use of single-dose Sputnik Light COVID-19 vaccine

enablePagination: false
maxItemsPerPage: 10
totalITemsFound:
maxPaginationLinks: 10
maxPossiblePages:
startIndex:
endIndex:

Metro Manila (CNN Philippines, May 7) — Russia has authorized the use of a single-dose coronavirus vaccine that is seen as a way to achieve herd immunity faster amid threats of new outbreaks.

In a statement, the Russian Direct Investment Fund (RDIF) announced that its Sputnik Light vaccine has been authorized for use in their country.

“The Sputnik Light vaccine significantly reduces the possibility of severe cases leading to hospitalization, with only one injection needed," said Kirill Dmitriev, CEO of the RDIF.

"The single dose regimen solves the challenge of immunizing large groups in a shorter time, which is especially important during the acute phase of the spread of coronavirus, achieving herd immunity faster,” he also said.

Developed by Moscow's Gamaleya Institute, the vaccine is based on a human adenoviral vector platform and would cost less than $10, the RDIF said. It also noted that Sputnik Light has a storage requirement of 2 to 8 degrees Celsius.

Based on analyzed data taken 28 days after a single shot was given, the RDIF said the vaccine demonstrated 79.4% efficacy on those who received it.

The administration was done during Russia’s mass vaccination program between Dec. 5, 2020, and April 15, 2021.

“Sputnik Light has proven effective against all new strains of coronavirus, as demonstrated by the Gamaleya Center during laboratory tests,” it added.

The vaccine has completed its Phase I and II Safety and Immunogenicity study.

Some of the results of the study said the vaccine can elicit the development of antigen specific Immunoglobulin G antibodies in 96.9% of individuals on the 28th day.

It also brings forth the development of virus neutralizing antibodies in 91.67% of vaccinees, and no serious adverse events occurred after receiving the single shot, the study also said.

Interim results for the Phase III clinical trials are expected this month, which involved 7,000 individuals from countries like Russia, the United Arab Emirates, and Ghana.

Dmitriev said Sputnik Light will be exported to other countries to help enhance their vaccination programs amid new threats caused by the virus, while the two-dose Sputnik V will remain as the main source of immunization in Russia.